Publication:
Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease

Simple item page
dc.contributor.authorA. Limsuwanen_US
dc.contributor.authorP. Pienvichiten_US
dc.contributor.authorP. Khowsathiten_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-06-21T08:19:06Z
dc.date.available2018-06-21T08:19:06Z
dc.date.issued2005-12-01en_US
dc.description.abstractWe present a report on children with severe pulmonary hypertension secondary to congenital heart disease who received 6 months of beraprost therapy. The children had an increase in intracardiac left-to-right shunt and a reduction of the pulmonary-to-systemic vascular resistance ratio, whereas the pulmonary artery pressure was not significantly changed. © Springer Science+Business Media, Inc. 2005.en_US
dc.identifier.citationPediatric Cardiology. Vol.26, No.6 (2005), 787-791en_US
dc.identifier.doi10.1007/s00246-005-0925-4en_US
dc.identifier.issn01720643en_US
dc.identifier.other2-s2.0-31144458147en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/16678
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=31144458147&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleBeraprost therapy in children with pulmonary hypertension secondary to congenital heart diseaseen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=31144458147&origin=inwarden_US

Files

Collections

Scopus 2001-2005